900% surge: CHM.CN Waverunner Capital CNQ to C$0.05 18 Feb 2026: liquidity cue

CHM.CN stock jumped 900.00% to C$0.05 on 18 Feb 2026 during Canada market hours on the CNQ exchange, a move driven by a sharp price gap from the prior close of C$0.005. The intraday range held at C$0.05 (low/high) while average volume historically sits near 28,908.00 shares. This high-volume mover note focuses on why the spike matters for traders, how the Healthcare sector compares, and what the balance-sheet and valuation metrics imply for short-term liquidity and risk.

Price action and volume context for CHM.CN stock

Waverunner Capital Inc. (CHM.CN) recorded a one-day price change of C$0.045 or 900.00%, moving to C$0.05 from a previous close of C$0.005. Reported current session volume was not published, but the stock’s 50-day average is C$0.04 and average daily shares are 28,908.00, highlighting that the percentage move likely reflects thin liquidity rather than broad investor re-rating.

CHM.CN stock: why the jump happened

There is no single public earnings or corporate press release tied to this exact move on 18 Feb 2026; the company website lists strategic investments and a June 2024 name change from Chemistree Technology. Small-cap microcap stocks like Waverunner frequently gap on limited buying, short-covering, or news leaks. Traders should treat the spike as a liquidity event until confirmed by clear corporate updates or filings.

Valuation and financials for Waverunner Capital Inc. (CHM.CN)

Key ratios show an EPS of -0.01 and a reported PE of -5.00, reflecting negative earnings. Market cap stands at C$37,211,650.00 with 744,233,000.00 shares outstanding. Cash per share is 0.01, book value per share is -0.11, and the current ratio is 0.16, underlining weak short-term liquidity and negative shareholders’ equity on a per-share basis.

Technical snapshot and trading signals for CHM.CN stock

Price averages are modest: 50-day average C$0.04 and 200-day average C$0.05, placing the current print at the 200-day mark. Year high is C$0.10 and year low C$0.05. The abrupt 900.00% intraday percent change combined with low average volume signals extreme volatility and potential bid-thin conditions for intraday traders.

Meyka AI rates CHM.CN with a score out of 100

Meyka AI rates CHM.CN with a score out of 100: 64.82 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects modest upside potential offset by negative earnings, weak current ratio, and microcap liquidity risks. Meyka AI provides this as an informational signal, not investment advice.

Outlook, sector comparison and risks for CHM.CN stock

Healthcare sector peers show average P/E around 20.19 and 1-year performance down 11.54%, so Waverunner sits outside typical sector fundamentals. Primary risks: thin liquidity, negative EPS, and negative book value per share. Opportunities include strategic venture stakes in renewables and biotech, but these are contingent on successful exits and capital markets access.

Final Thoughts

Key takeaways: CHM.CN stock moved sharply — 900.00% to C$0.05 on 18 Feb 2026 — driven by a thin-market liquidity event rather than a confirmed earnings beat or clear corporate disclosure. Financials show EPS -0.01, PE -5.00, negative book value per share -0.11, and a constrained current ratio 0.16, all pointing to structural risk for buy-and-hold investors. Meyka AI’s forecast model projects a 12-month target of C$0.08, implying an upside of 60.00% versus the current C$0.05; forecasts are model-based projections and not guarantees. Traders focused on high-volume movers should prioritise verified news, watch for volume confirmation above the 28,908.00 average, and consider tight risk limits. For company filings and background see the company site and profile pages below and our internal CHM.CN stock page for live signals and alerts on Meyka AI’s platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.